Skip to main content

Advertisement

Advertisement

Bill Gates says altered mosquitoes are next weapon in Malaria fight

BOSTON (Massachusetts) — Bring on the genetically modified mosquitoes, Mr Bill Gates says.

An Aedes aegypti mosquito. Photo: Reuters

An Aedes aegypti mosquito. Photo: Reuters

BOSTON (Massachusetts) — Bring on the genetically modified mosquitoes, Mr Bill Gates says.

In recent years, biologists armed with a new gene-editing technology have proposed altering mosquitoes so they are more resistant to diseases like malaria and dengue. Using a mechanism known as a “gene drive”, the researchers say they can quickly push an alteration through an entire species.

“In less in five years, I think there’s a good chance it will be out there,” Mr Gates said in an interview with Bloomberg News before speaking at a conference of the American Society for Microbiology in Boston.

In normal reproduction, a mosquito carrying one copy of an altered gene passes it on to 50 per cent of its offspring. In a gene drive, an engineered segment of DNA is inserted in the mosquito that causes 100 per cent of the offspring to inherit the altered gene, dramatically increasing the rate of spread.

“Gene drives, I do think, over the next three to five years will be developed in a form that will be extremely beneficial for knocking down” mosquito populations, Mr Gates said. “Of course, that makes it a key tool to reduce malaria deaths.”

CONTROVERSIAL APPROACH

Scientists have said that they have successfully created malaria-resistant mosquitoes in a lab that passed on the trait to 99.5 per cent of their progeny. While the technology may work, it is controversial. Some researchers have warned that gene drives may not be safe — what if the targeted species cross-breed with another organism? What if released mosquitoes develop spontaneous, unintended mutations? — and have called for more regulation.

“My basic belief is that children dying of malaria is a bad thing, and that we should be able to meet these objections,” Mr Gates said. “But there’s still a fair bit of work to be done. Nothing is ready to be deployed today.”

Through the Bill and Melinda Gates Foundation, the Microsoft co-founder has waged a lengthy battle against malaria, committing almost US$2 billion (S$2.7 billion) in grants to combat the disease since launching the foundation in 2000. There were about 214 million malaria cases and 438,000 deaths from the disease last year, according to the World Health Organization.

INFECTED BUGS

In the meantime, Mr Gates says a different mosquito project already has been deployed — one that the foundation started funding more than 15 years ago. The mosquitoes are infected with a bacterium called Wolbachia, which can block the transmission of dengue and the Zika virus. Wolbachia mosquitoes may be deployed in Colombia and Brazil in the next year, Mr Gates said.

The idea of a gene drive is not new, though it has been helped by the use of Crispr-Cas9, a gene-editing technique that is cheaper and faster than previous methods. Working like a pair of molecular scissors, Crispr can precisely cut out, and even replace, sections of DNA. It has given researchers an unprecedented ability to direct where DNA should be edited.

Crispr-based therapeutics for genetic diseases also are being developed, including by Editas Medicine, a Cambridge, Massachusetts-based biotechnology firm backed by Mr Gates.

Mr Gates says he hopes to see gene editing used against HIV. His foundation has funded older gene-editing efforts against HIV, which were less efficient than Crispr. “HIV is still a lifelong disease, and any type of cure approach or some sort of way that you’d protect somebody on a lifelong basis, that would be invaluable, but that’s at a very early stage.”

While Editas is not working on HIV, “it’s fantastic that they’re starting with some eye diseases, looking at some things that have been completely insoluble that they may have solutions for”, he said. BLOOMBERG

Read more of the latest in

Advertisement

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.